The market's upward trajectory is fueled by the rising prevalence of chronic autoimmune diseases and hematologic malignancies, which necessitate long-term, recurring treatment cycles. Healthcare providers are increasingly integrating targeted biologics into standard clinical guidelines, supported by expanding hospital infusion infrastructure and specialty pharmacy networks. According to Anurag Sharma, a senior healthcare analyst at Future Market Insights, these therapies are transitioning from niche specialist options into foundational elements of long-term disease management, bolstered by improved reimbursement frameworks and growing clinical confidence.

Anti-CD20 monoclonal antibodies currently command a 70% market share, remaining the preferred choice due to their established safety profiles and decades of clinical validation. While next-generation therapies continue to emerge, the sector’s commercial backbone remains rooted in these proven biologics. Geographically, India is expected to lead global growth with a projected 11.2% CAGR, as emerging healthcare systems modernize their infrastructure and improve patient access to advanced immunology care.